{"id":{"repo_id":"wfu","oai_identifier":"oai:wakespace.lib.wfu.edu:10339/33429"},"canonical_url":"https://search.dev.ndltd.org/etd/wfu/oai:wakespace.lib.wfu.edu:10339/33429","repository":{"repo_id":"wfu","name":"Wake Forest University","base_url":"https://wakespace.lib.wfu.edu/oai/request"},"display":{"title":"SELECTION/CONSTRUCTION AND CHARACTERIZATION OF NOVEL PEPTIDE AND RECOMBINANT PROTEIN AGENTS TARGETING INTERLEUKIN 13 RECEPTOR ALPHA 2 IN GLIOBLASTOMA MULTIFORME","abstract":"Glioblastoma multiforme (GBM) is a primary brain tumor of dismal prognosis. Patients with GBM have a median survival rate of 14.5 months inspite of multimodality treatment involving surgery, radio- and chemotherapy. This warrants an intensive search for efficient new therapies. Interleukin 13 receptor alpha 2 (IL-13Rα2) is an internalized, plasma membrane receptor for IL-13. IL-13Rα2 is over-expressed in around 75 percent of GBM patients. One of our goals is to develop specific therapeutic delivery vehicles and imaging agents targeting IL-13Rα2.","abstract_html":"Glioblastoma multiforme (GBM) is a primary brain tumor of dismal prognosis. Patients with GBM have a median survival rate of 14.5 months inspite of multimodality treatment involving surgery, radio- and chemotherapy. This warrants an intensive search for efficient new therapies. Interleukin 13 receptor alpha 2 (IL-13Rα2) is an internalized, plasma membrane receptor for IL-13. IL-13Rα2 is over-expressed in around 75 percent of GBM patients. One of our goals is to develop specific therapeutic delivery vehicles and imaging agents targeting IL-13Rα2.","abstract_has_math":false,"creators":["Pandya, Hetal Vinod"],"institution":"Wake Forest University","degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2011,"date_issued":"2011","date_published":"2011","updated_at":"2026-07-27T22:01:14Z","subjects":["blood-brain tumor barrier"],"languages":["en"],"rights":[],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/10339/33429","outbound_label":"Handle","outbound_source":"dc:identifier.uri"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:creator","label":"Author","values":["Pandya, Hetal Vinod"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2011-07-14T20:35:08Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2012-01-14T09:30:11Z"]},{"key":"dc:date.issued","label":"Date","values":["2011"]},{"key":"dc:publisher","label":"Institution","values":["Wake Forest University"]},{"key":"dc:type","label":"Dc Type","values":["Dissertation"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["blood-brain tumor barrier"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://hdl.handle.net/10339/33429"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Glioblastoma multiforme (GBM) is a primary brain tumor of dismal prognosis. Patients with GBM have a median survival rate of 14.5 months inspite of multimodality treatment involving surgery, radio- and chemotherapy. This warrants an intensive search for efficient new therapies. Interleukin 13 receptor alpha 2 (IL-13Rα2) is an internalized, plasma membrane receptor for IL-13. IL-13Rα2 is over-expressed in around 75 percent of GBM patients. One of our goals is to develop specific therapeutic delivery vehicles and imaging agents targeting IL-13Rα2."]},{"key":"dc:title","label":"Title","values":["SELECTION/CONSTRUCTION AND CHARACTERIZATION OF NOVEL PEPTIDE AND RECOMBINANT PROTEIN AGENTS TARGETING INTERLEUKIN 13 RECEPTOR ALPHA 2 IN GLIOBLASTOMA MULTIFORME"]}]}],"canonical_facts":{"dc:creator":["Pandya, Hetal Vinod"],"dc:date.accessioned":["2011-07-14T20:35:08Z"],"dc:date.available":["2012-01-14T09:30:11Z"],"dc:date.issued":["2011"],"dc:description.abstract":["Glioblastoma multiforme (GBM) is a primary brain tumor of dismal prognosis. Patients with GBM have a median survival rate of 14.5 months inspite of multimodality treatment involving surgery, radio- and chemotherapy. This warrants an intensive search for efficient new therapies. Interleukin 13 receptor alpha 2 (IL-13Rα2) is an internalized, plasma membrane receptor for IL-13. IL-13Rα2 is over-expressed in around 75 percent of GBM patients. One of our goals is to develop specific therapeutic delivery vehicles and imaging agents targeting IL-13Rα2."],"dc:identifier.uri":["http://hdl.handle.net/10339/33429"],"dc:language.iso":["en"],"dc:publisher":["Wake Forest University"],"dc:subject":["blood-brain tumor barrier"],"dc:title":["SELECTION/CONSTRUCTION AND CHARACTERIZATION OF NOVEL PEPTIDE AND RECOMBINANT PROTEIN AGENTS TARGETING INTERLEUKIN 13 RECEPTOR ALPHA 2 IN GLIOBLASTOMA MULTIFORME"],"dc:type":["Dissertation"]},"updated_at":"2026-07-27T22:01:14Z"}